Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan.

Summary

• Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 13 shares of common stock on May 20, 2024.
• The shares were acquired at a price of $783.18 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Sulzberger's separation from service.
• Following this transaction, Ms. Sulzberger directly owns 2,141 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a positive but not extraordinary sentiment. The director's participation in the deferral plan suggests confidence in the company's long-term prospects.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of a deferral plan aligns director compensation with long-term company performance.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

Director share acquisitions are a common practice and are often seen as a positive sign of confidence in the company's future prospects.

Comparison to Industry Standards

• Director share acquisitions are a common practice across the pharmaceutical industry.
• Many companies offer deferral plans as part of their director compensation packages, similar to Eli Lilly's plan.
• The number of shares acquired is relatively small, which is typical for individual director transactions.

Stakeholder Impact

• The share acquisition by a director may be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Form 4, LLY